Loading...

TNYA TENAYA THERAPEUTICS INC US FDA Inspections 8-K Filing

TNY

TNY

TENAYA THERAPEUTICS INC

(TNYA)

2025 8-K

Financial Results Announcement

Financial Results Announcement

Collaboration Agreement

NASDAQ Compliance Notice

Director Resignation

Public Offering Announcement

FDA Approval Update

Financial Results Report

FDA Clinical Hold

Financial Statements

Financial Statements

Nasdaq Compliance

Restructuring Plan

Earnings Announcement

Public Offering

Management Changes

Stock Option Repricing

Clinical Trial Update

Management Change

Earnings Announcement

Financial Results and Manag...

Resignation of CFBO

Resignation of Director

Annual Meeting and Voting R...

Financial Results and Workf...

Earnings Reports

Underwriting Agreement for ...

Earnings Reports

Earnings Reports

Amendments to Executive Sev...

Earnings Reports

Amended and Restated Bylaws

Regulation FD Disclosure

Earnings Reports

External Links:

On December 11, 2025, Tenaya Therapeutics announced that the FDA lifted a clinical hold on their MyPEAK-1 gene therapy trial and provided initial positive data on their TN-401 gene therapy, showing clinical improvement in patients.

AI Assistant

TENAYA THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.